Research Triangle Park, N.C.-based TransEnterix said it expects to post sales of $6.0 million to $6.3 million for the three months ended ended June 30, 2018, up 300% to 320% compared with Q2 2017. Analysts on The Street were looking for sales of $5.4 million.
TransEnterix also revealed another sale of its Senhance device via distributor for Europe, Middle East, & Africa last month, taking the June sales tally to four systems.
“We had a strong second quarter as we continued to drive sales of Senhance globally while at the same time making significant progress towards our 2018 goals, including the expansion of Senhance’s indications for use and portfolio of instruments,” said Todd M. Pope, President and CEO at TransEnterix. “We look forward to continuing to build upon the momentum we developed during the first half of the year to drive the widespread adoption of Senhance.”
TransEnterix said it had about $98 million in cash & equivalents as of June 30.
TRXC shares were up 8.7% to $4.74 apiece today in pre-market trading.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.